Giona S (2022) The Epidemiology of Testicular Cancer. In: Barber N, Ali A, editors. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; [cited 2024 Aug 7]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK585983/

Ehrlich Y, Margel D, Lubin MA, Baniel J (2015) Advances in the treatment of testicular cancer. Transl Androl Urol 4(3):38190–38390

Google Scholar 

Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA et al (2022) Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol 33(4):362–375

Article  CAS  PubMed  Google Scholar 

Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15(9):1377–1399

Article  CAS  PubMed  Google Scholar 

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21(8):1513–1523

Article  CAS  PubMed  Google Scholar 

Heinzelbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J et al (2022) Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol 1–13.

Maroto P, Anguera G, Martin C (2018) Long-term toxicity of the treatment for germ cell-cancer. A review. Crit Rev Oncol Hematol 121:62–67

Article  CAS  PubMed  Google Scholar 

Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J et al (2012) Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol Off J Am Soc Clin Oncol 30(30):3752–3763

Article  Google Scholar 

Hu B, Daneshmand S (2018) Retroperitoneal lymph node dissection as primary treatment for metastatic seminoma. Adv Urol 2018:7978958

Article  PubMed  PubMed Central  Google Scholar 

Baniel J, Sella A (1999) Complications of retroperitoneal lymph node dissection in testicular cancer: Primary and post-chemotherapy. Semin Surg Oncol 17(4):263–267

Article  CAS  PubMed  Google Scholar 

Tran V, Gibson L, Sengupta S (2020) Retroperitoneal lymph node dissection for germ cell tumour. Transl Androl Urol 9(6):3103–3111

Article  PubMed  PubMed Central  Google Scholar 

Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169(5):1710–1714

Article  PubMed  Google Scholar 

Heinzelbecker J, Katzmarzik M, Weiss C, Trojan L, Michel MS, Haecker A (2011) Changes of stage, predictive factors and adjuvant treatment modalities in seminomatous testicular cancer from 1987 to 2007 and their impact on the status of metastasis, recurrence-free and overall survival: a single-center analysis. Urol Int 87(3):282–287

Article  CAS  PubMed  Google Scholar 

Bumbasirevic U, Zivkovic M, Petrovic M, Coric V, Lisicic N, Bojanic N (2022) Treatment options in stage I seminoma. Oncol Res 30(3):117–28

Article  PubMed  Google Scholar 

Mezvrishvili Z, Managadze L (2006) Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol 38(3–4):615–619

PubMed  Google Scholar 

Warszawski N, Schmücking M (1997) Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol 31(4):355–359

Article  CAS  PubMed  Google Scholar 

Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K et al (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 1(21):v140–v146

Article  Google Scholar 

Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA et al (2023) Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. https://doi.org/10.1200/JCO.22.00624

Hiester A, Che Y, Lusch A, Kuß O, Niegisch G, Lorch A et al (2023) Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 84(1):25–31

Article  CAS  PubMed  Google Scholar 

Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D (2024) Retroperitoneal lymph node dissection in clinical stage IIA/B metastatic seminoma: results of the cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma (COTRIMS). Eur Urol Oncol 7(1):122–127

Article  PubMed  Google Scholar 

Cazzaniga W, Kinsella N, Reid A, Huddart R, Mayer E, Nicol D (2023) A0753-outcomes of minimally invasive retroperitoneal lymph node dissection (primary MI- RPLND) followed by adjuvant carboplatin (AUC7) for clinical stage IIa/b seminoma. Eur Urol 1(83):S1065

Article  Google Scholar 

Thor A, Negaard HFS, Bergdahl AG, Almås B, Larsen SM, Lundgren PO et al (2024) Primary retroperitoneal lymph node dissection as treatment for low-volume metastatic seminoma in a population-based cohort: the Swedish Norwegian testicular cancer group experience. Eur Urol Open Sci 1(65):13–19

Article  Google Scholar 

Tandstad T, Kjellman A, Almås B, GrenaboBergdahl A, Cohn-Cedermark GE, Gerdtsson A et al (2023) Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne. J Clin Oncol 41(16_suppl):5008–5008

Article  Google Scholar 

Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG (2005) Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther 5(5):869–874

Article  PubMed  Google Scholar 

Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR et al (2012) 2–18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol Off J Eur Soc Med Oncol 23(1):59–64

Article  CAS  Google Scholar 

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22(6):1034–1039

Article  PubMed  Google Scholar 

Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F et al (2018) Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell cancer group registry. J Clin Oncol Off J Am Soc Clin Oncol JCO1800210.